Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 136

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Adenoid cystic carcinoma of salivary gland

Not yet recruiting

Efficacy and safety of lutetium‑177 vipivotide tetraxetan with gozetotide in patients with progressive adenoid cystic carcinoma of the salivary glands

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

Triple negative breast cancer

Not yet recruiting

Assessing the prognostic value of PSMA‑T4 SPECT/CT imaging in patients with triple‑negative breast cancer undergoing neoadjuvant therapy

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Narodowe Centrum Badan Jadrowych

Acquired C1 inhibitor deficiency

Not yet recruiting

Efficacy and Safety of Berotralstat for Preventing Angioedema Attacks in Patients with Acquired Angioedema due to C1 Inhibitor Deficiency

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Berotralstat
  • Sponsor:Policlinico San Donato S.p.A.

Adenoid cystic carcinoma

Not yet recruiting

Study of Sodium Valproate and Lenvatinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Breast cancer

Not yet recruiting

Premedication with dexamethasone to prevent interstitial lung disease in breast cancer patients receiving trastuzumab deruxtecan

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Cutaneous T-cell lymphoma

Not yet recruiting

Topical delgocitinib safety study in patients with cutaneous T‑cell lymphoma (mycosis fungoides)

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Region Midtjylland

Paraganglion neoplasm+1

Not yet recruiting

Evaluation of D-Glucose-13C6 Test for Detecting SDHx Mutations in Patients with Pheochromocytoma or Paraganglioma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Assistance Publique Hopitaux De Paris

Neuroblastoma

Not yet recruiting

Feasibility Study of AloCelyvir and Autologous Tumor‑Infiltrating T Lymphocytes in Children and Young Adults with High‑Risk Relapsed/Refractory Neuroblastoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa

Follicular lymphoma

Not yet recruiting

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Malignant melanoma stage IV+1

Not yet recruiting

Phase Ib/II study of momelotinib with nivolumab or pembrolizumab in unresectable stage III/IV cutaneous melanoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Karolinska University Hospital

Acute myeloid leukaemia+1

Not yet recruiting

Safety and feasibility study of CARCIK‑CD123/33 cell therapy in adult and pediatric patients with relapsed or refractory AML and BPDCN

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Fondazione IRCCS San Gerardo Dei Tintori

Triple negative breast cancer

Not yet recruiting

Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Institut Paoli-Calmettes

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.